Advancing drug development for systemic sclerosis by prioritizing findings from human genetic association studies.
No Thumbnail Available
Authors
Hughes M.
McMahan Z.H.
Assassai S.
Denton C.P.
Providencia, R.
Contact
Check for full-text access
Issue Date
2026
Type
Article
Language
Keywords
Alternative Title
Abstract
Objectives SSc is a rare rheumatological disease associated with significant morbidity and mortality. Despite significant recent international clinical trial activity, the yield of approved compounds has been disappointingly low. Our aim was to identify and prioritize potential 'druggable' targets with insights from human genetics, by integrating the available evidence with publicly available bioinformatics sources relevant for SSc drug development. Methods Genetic variants for SSc were identified through a search of the GWAS Catalog, and the associated-mapped genes were cross-referenced with the OpenTargets platform for drug interactions. Confirmation/validation was demonstrated through structured literature searches and review of the evidence on MEDLINE and ClinialTrials.gov for each individual drug and its association with SSc. Results We identified 89 unique drugs, none of which is included in existing SSc guidelines/recommendations. Amlitelimab (anti-OX40L mAb) is currently being explored in CONQUEST (Platform Clinical Study for Conquering Scleroderma), a multicentre randomized controlled platform trial for SSc interstitial lung disease. Key groupings of drug therapies were (i) female sex hormones and function, (ii) neurotransmitter-targeting therapies, and (iii) inflammatory-fibrotic pathways. The Janus kinase (JAK)/STAT pathway is an attractive therapeutic target in SSc, targeting known pathobiology. Conclusion Our systematic approach, combining evidence from different bioinformatics platforms, has identified drug opportunities for repurposing/druggable targets for SSc. A novel and unexpected finding was the identification of multiple neurotransmitter-targeting drug therapies, particularly relevant to SSc-related RP and gastrointestinal involvement. Future studies of these candidates for SSc drug repurposing, many of which are widely available and often inexpensive, are indicated. Copyright © The Author(s) 2026. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Description
Citation
Publisher
License
Journal
Rheumatology
Volume
65